TORONTO, ONTARIO--(Marketwire - June 04, 2008) - PharmEng International Inc. (TSX VENTURE: PII), a full-service consulting and contract manufacturing company, today reported its results for the period ended March 31, 2008. The Company had a transitional quarter where for the first time in Company history, the revenue generated from the contract manufacturing division (operating as Keata Pharma Inc. "Keata") exceeded the revenue generated from the consulting division (operating as PharmEng Technology Inc. "PTI"). Also in the quarter, for the first time in Keata's history, contract manufacturing contributed significantly to earnings before interest, taxes, depreciation and amortization. These two transitional milestones are the beginnings of a future trend for the Company where contract manufacturing revenues and growth out pace those of the traditional consulting division which is forecasted to provide steady but not as dramatic growth.
